Navigation Links
Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy

ept) or placebo (Period B) and time to disease flare and safety were assessed, and an open-label phase designed to assess efficacy and long-term safety (Period C). Children in periods A and B remained on a stable dose of MTX and children in Period C were permitted one of three DMARDs in addition to ORENCIA. Data from Period C will be presented tomorrow. Results from Periods A and B were presented at the of Rheumatology Annual Scientific Meeting in November 2006.

Fifty-nine children randomized to placebo in Period B participated in Period C to receive open label treatment with ORENCIA. Thirty-three of them experienced a flare while 26 did not.

Everyone in Period C received 10 mg/kg of ORENCIA approximately every 28 days. Of the 33 children who received placebo and experienced disease flares during the Period B protocol-mandated withdrawal phase of up to six months, 80 percent had an ACR Pedi 30 response, 70 percent had an ACR Pedi 50 response, 50 percent had an ACR Pedi 70 Response and 27 percent had an ACR Pedi 90 response after re-introduction of therapy with ORENCIA in Period C.

Of the 26 children who received placebo during Period B who did not experience disease flares and then chose to receive open-label ORENCIA treatment during Period C, 76 percent had an ACR Pedi 30 response, 68 percent had an ACR Pedi 50 response, 60 percent had an ACR Pedi 70 Response and 36 percent had an ACR Pedi 90 response after re-introduction of therapy with ORENCIA in Period C.

Of the children who completed Period C, four (6.7 percent) children previously treated with placebo in Period B reported serious adverse events (SAEs) versus five (5.5 percent) children continuously treated with ORENCIA. All SAEs were considered unrelated to ORENCIA according to the investigator. None of these children discontinued due to an adverse event (AE). In addition, no child previously treated with placebo in Period B had an acute infusion reaction during the first infusion
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
5. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
6. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
11. Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia
Post Your Comments:
(Date:7/31/2014)... 2014  Decision Resources Group is launching an extension ... to now include ChinaTrack; the new capabilities track the ... interactive dashboard providing detailed brand-level share tracking and analytics. ... level. Other key capabilities of the new ... addition to end-user surveys of healthcare facilities, ChinaTrack data ...
(Date:7/31/2014)... -- Hovione today announced that its API plant ... a pre-approval inspection by the US Food and Drug Administration ... Consumer Safety Officer, Ms. Britanny Terhar , lasted 5 ... and concluded on the 25 th . The inspection confirmed ... of Good Manufacturing Practices (GMP) and no Form 483 observations ...
(Date:7/31/2014)... NEW YORK and VIENNA , ... today at a press conference in New York ... of PD01A, a vaccine against Parkinson,s disease. PD01A is the ... target, to enter clinical testing. The Michael J. ... a $ 1.5 million grant, and presented at the press ...
Breaking Medicine Technology:Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2Successful FDA Inspection at Hovione's API Manufacturing Plant in Cork, Ireland 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4
... April 21, 2011 iMD Companies (ICBU.PK) is pleased ... Testing Facility (IDTF), Optimum Mobile Imaging LLC, which increases ...  The acquisition was done with cash and restricted stock ... can be found at www.OMIAZ.com .   OMI ...
... MiMedx Group, Inc.  (OTCBB: MDXG), an integrated developer, ... today the Company,s attendance at the upcoming International Society ... 26 – 29, 2011.  The meeting will be held ... / Palazzo Hotels in Las Vegas, Nevada.   ...
Cached Medicine Technology:iMD Companies, Inc. Acquires OMI LLC and Files Financials for 2010 2iMD Companies, Inc. Acquires OMI LLC and Files Financials for 2010 3MiMedx to Attend International Society for the Advancement of Spine Surgery Annual Meeting 2
(Date:7/31/2014)... 31, 2014 Leelanau Peninsula’s newest winery, ... 2014 at 7788 East Horn Road in Lake Leelanau. Joining ... , Aurora Cellars is the 25th winery along the trail. ... popular wine tour events, making its trail event debut during ... , Owners David and Faye Mathia opened the boutique ...
(Date:7/31/2014)... 2014 In today’s world, a good night’s ... Snoring and sleep apnea (a medical problem where the airway ... bed partners of the rest they need to face their ... snores and 20 million people in the United States alone ... and treated; and of those treated, many cannot tolerate their ...
(Date:7/31/2014)... has announced that they are now offering a new ... Review of Sexual Satisfaction . The course is ... Clinical and Health Psychology. , This CE course has ... accurate information about sexual satisfaction so that healthcare professionals ... provides a systematic review of 197 research publications in ...
(Date:7/31/2014)... July 31, 2014 In many states and ... for proper storage of necessary life saving drugs. This requirement ... there is still a high number of ambulances without proper ... who steals the narcotics and even replaces the vital pain ... none. As seen in the case in Baraboo, Wisconsin last ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 In today’s world, ... difficult to get. Snoring and sleep apnea (a medical problem ... people and their bed partners of the rest they need ... of the population snores and 20 million people in the ... have been diagnosed and treated; and of those treated, many ...
Breaking Medicine News(10 mins):Health News:Aurora Cellars Joins the Leelanau Peninsula Wine Trail 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Company Provides New Course on Sexual Satisfaction 2Health News:Company Provides New Course on Sexual Satisfaction 3Health News:New MedixSafe Alert - Ambulances Must Have A Medical Safe, Narcotics Cabinet, or Drug Locker 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... In a comparison of anticoagulants and stents for use ... and tirofiban had similar outcomes for some cardiac measures ... received stents that released the drug sirolimus had a ... months than patients who received uncoated stents, according to ...
... March 29 The second annual,National Walk for ... and raised $1.5 million to help build awareness ... to raise much-needed funds. The event,was sponsored by ... http://www.newscom.com/cgi-bin/prnh/20080329/17897 ), The stars coming ...
... 2008) -- Physician-scientists from NewYork-Presbyterian Hospital/Columbia University Medical ... the American College of Cardiology,s 57th Annual Scientific ... Among the most significant presentations are the following: ... Transplant Allograft Vasculopathy , Dr. Jeffrey ...
... room for improvement in balancing seizure control ... and medication-related side ... of the nation,s,largest event dedicated to the epilepsy community, ... in response to a,new national survey uncovering key challenges ...
... Consultancy to Address Circle of Patient Care, ... Mike Marolt, president of St.,Paul-based eq-life(R), announced ... to provide pharmacy operations consulting to,hospital organizations ... a,multi-year agreement with Omaha-based Alegent Health to ...
... Ranks above National Average in Overall Patient Satisfaction and Other ... ... The Hospital Quality Alliance today,released the first Hospital Consumer Assessment of ... care as rated by patients themselves. Hospital for Special Surgery,(HSS) in New ...
Cached Medicine News:Health News:Comparison of anticoagulants for angioplasty show similar outcomes 2Health News:National Walk for Epilepsy Brings People and Celebrities Together for Epilepsy 2Health News:NewYork-Presbyterian/Columbia physician-scientists present at ACC's 57th Annual Scientific Session 2Health News:NewYork-Presbyterian/Columbia physician-scientists present at ACC's 57th Annual Scientific Session 3Health News:Leading Epilepsy Advocates Propose Strategies to Heighten Treatment Expectations and Close Patient and Physician Communication Gaps 2Health News:Leading Epilepsy Advocates Propose Strategies to Heighten Treatment Expectations and Close Patient and Physician Communication Gaps 3Health News:Leading Epilepsy Advocates Propose Strategies to Heighten Treatment Expectations and Close Patient and Physician Communication Gaps 4Health News:Leading Epilepsy Advocates Propose Strategies to Heighten Treatment Expectations and Close Patient and Physician Communication Gaps 5Health News:eq-life(R) and Fairview Pharmacy Services Announce Multi-Year Consulting Contract with Alegent Health 2Health News:eq-life(R) and Fairview Pharmacy Services Announce Multi-Year Consulting Contract with Alegent Health 3Health News:Hospital for Special Surgery Reports Scores on HCAHPS Survey 2Health News:Hospital for Special Surgery Reports Scores on HCAHPS Survey 3
For the quantitative in vitro determination of Digoxin in human serum....
For the quantitative in vitro determination of Microalbumin in urine....
Quantitative determination of Fibrinogen (Clauss Method). Freeze-dried human thrombin (~100NIH units/mL) with heparin inhibitor and calcium....
Determination of Prothrombin Time (PT)by STA Analyzers (ISI~1.8).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
Medicine Products: